NASDAQ:RPHM

Reneo Pharmaceuticals (RPHM) Stock Forecast, Price & News

$7.58

+0.49 (+6.91%)

(As of 05:12 PM ET)

Compare

Today's Range: $7.00
▼
$7.97
50-Day Range: $5.44
▼
$8.03
52-Week Range: $1.79
▼
$11.30

Volume: 104,212 shs
Average Volume: 116,214 shs
Market Capitalization: $256.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.00

Reneo Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 282.7% Upside
$30.00 Price Target
Short Interest: Bearish
10.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.43
Based on 2 Articles This Week
Insider Trading: Selling Shares
$808,125 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

710th out of 968 stocks

Pharmaceutical Preparations Industry

321st out of 445 stocks

3.5

Analyst's Opinion

Consensus Rating
Reneo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.00, Reneo Pharmaceuticals has a forecasted upside of 282.7% from its current price of $7.84.
Amount of Analyst Coverage
Reneo Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
10.34% of the float of Reneo Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Reneo Pharmaceuticals has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Reneo Pharmaceuticals has recently increased by 16.67%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Reneo Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reneo Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RPHM.

3.0

News and Social Media Coverage

News Sentiment
Reneo Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Reneo Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for RPHM on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Reneo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reneo Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $808,125.00 in company stock.
Percentage Held by Insiders
17.90% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
85.01% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Reneo Pharmaceuticals are expected to remain at ($2.44) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Reneo Pharmaceuticals is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Reneo Pharmaceuticals is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Reneo Pharmaceuticals has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Reneo Pharmaceuticals (NASDAQ:RPHM) Stock

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

RPHM Price History

30 days | 90 days | 365 days | Advanced Chart

RPHM Stock News Headlines

September 20, 2023 | finance.yahoo.com

Reneo Pharmaceuticals (NASDAQ:RPHM) Is In A Good Position To Deliver On Growth Plans

September 8, 2023 | msn.com

HC Wainwright & Co. Reiterates Reneo Pharmaceuticals (RPHM) Buy Recommendation

September 22, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 8, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Reneo Pharmaceuticals (RPHM)

August 28, 2023 | msn.com

HC Wainwright starts Reneo at buy, sees possible 2025 launch for lead drug

August 28, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Reneo Pharmaceuticals (RPHM) with Buy Recommendation

August 10, 2023 | finanznachrichten.de

Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results

August 10, 2023 | finance.yahoo.com

Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) stock price dropped 10% last week; private equity firms would not be happy

September 22, 2023 | Weiss Ratings (Ad)

Overlooked AI Stock Gets Urgent "Buy"

We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.

August 10, 2023 | finance.yahoo.com

Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results

July 17, 2023 | msn.com

Reneo Pharmaceuticals: Promising Potential For PPARδ Agonist, Pending Safety Evaluation

July 3, 2023 | markets.businessinsider.com

Reneo Pharmaceuticals (RPHM) Receives a New Rating from Bank of America Securities

June 30, 2023 | finance.yahoo.com

Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum

June 26, 2023 | finance.yahoo.com

Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices

June 15, 2023 | finance.yahoo.com

Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023

May 31, 2023 | finance.yahoo.com

Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference

May 31, 2023 | finance.yahoo.com

Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference

May 26, 2023 | seekingalpha.com

RPHM Reneo Pharmaceuticals, Inc.

May 21, 2023 | finance.yahoo.com

Insiders Pour $1 Million Each Into These 2 ‘Strong Buy’ Stocks⁠ — Here’s Why Wall Street Thinks They Could Double (or More)

May 11, 2023 | msn.com

Reneo Pharmaceuticals: Q1 Earnings Insights

May 11, 2023 | finanznachrichten.de

Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results

May 11, 2023 | finance.yahoo.com

Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results

May 9, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Reneo Pharmaceuticals (RPHM)

May 4, 2023 | marketwatch.com

Reneo Pharma Shares Drop 21% After $55M Public Offering Prices

May 4, 2023 | finance.yahoo.com

Reneo Announces Pricing of Public Offering of Common Stock

May 3, 2023 | msn.com

Reneo Pharmaceuticals launches stock offering, shares fall 10%

May 3, 2023 | finance.yahoo.com

Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock

See More Headlines

Receive RPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RPHM Company Calendar

Last Earnings: 8/10/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RPHM
CUSIP: N/A
CIK: 1637715
Web: reneopharma.com
Phone: 858-283-0280
Fax: N/A
Employees: 51
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $30.00
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +282.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -56.76%
Return on Assets: -51.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.65
Quick Ratio: 10.65

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.08 per share
Price / Book: 1.92

Miscellaneous

Outstanding Shares: 33,800,000
Free Float: 27,751,000
Market Cap: $264.99 million
Optionable: Not Optionable
Beta: 1.14

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Michael G. Grey (Age 70)
Founder & Exec. Chairman
Comp: $100k

Mr. Gregory J. Flesher (Age 53)
Pres, CEO & Director
Comp: $800.45k

Mr. Michael P. Cruse (Age 51)
Chief Operating Officer
Comp: $535.47k

Ms. Ashley F. Hall J.D. (Age 51)
Chief Devel. Officer
Comp: $661.55k

Ms. Jennifer P. Lam
Sr. VP of Fin., Principal Financial & Accounting Officer

Dr. Alejandro Dorenbaum M.D. (Age 62)
Chief Medical Officer

Ms. Lynn Purkins Ph.D.
Sr. VP of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RPHM Stock - Frequently Asked Questions

Should I buy or sell Reneo Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RPHM shares.
View RPHM analyst ratings or view top-rated stocks.
What is Reneo Pharmaceuticals' stock price forecast for 2023?: 2 Wall Street analysts have issued 12-month price targets for Reneo Pharmaceuticals' stock. Their RPHM share price forecasts range from $30.00 to $30.00. On average, they anticipate the company's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 282.7% from the stock's current price.
View analysts price targets for RPHM or view top-rated stocks among Wall Street analysts.
How have RPHM shares performed in 2023?: Reneo Pharmaceuticals' stock was trading at $2.33 at the beginning of 2023. Since then, RPHM shares have increased by 236.5% and is now trading at $7.84.
View the best growth stocks for 2023 here.
When is Reneo Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our RPHM earnings forecast.
How were Reneo Pharmaceuticals' earnings last quarter?: Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) announced its earnings results on Thursday, August, 10th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.10.
When did Reneo Pharmaceuticals IPO?: (RPHM) raised $101 million in an initial public offering (IPO) on Friday, April 9th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Reneo Pharmaceuticals' stock symbol?: Reneo Pharmaceuticals trades on the NASDAQ under the ticker symbol "RPHM."
Who are Reneo Pharmaceuticals' major shareholders?: Reneo Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Carlyle Group Inc. (8.02%), Eventide Asset Management LLC (5.20%), Franklin Resources Inc. (4.00%), Great Point Partners LLC (3.22%), ExodusPoint Capital Management LP (1.65%) and BlackRock Inc. (1.36%). Insiders that own company stock include Ashley Hall, Bali Muralidhar, Gregory J Flesher, Holdings A/S Novo, Michael Cruse, Niall O'donnell, Venture Fund Iii L Rivervest and Vineet R Jindal.
View institutional ownership trends.
How do I buy shares of Reneo Pharmaceuticals?: Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Reneo Pharmaceuticals' stock price today?: One share of RPHM stock can currently be purchased for approximately $7.84.
How much money does Reneo Pharmaceuticals make?: Reneo Pharmaceuticals (NASDAQ:RPHM) has a market capitalization of $264.99 million. The company earns $-51,960,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.
How can I contact Reneo Pharmaceuticals?: The official website for the company is reneopharma.com. The company can be reached via phone at 858-283-0280 or via email at investors@reneopharma.com.

This page (NASDAQ:RPHM) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial